Zobrazeno 1 - 10 of 206 pro vyhledávání: '"Hervé Lena"'
1
Akademický článek
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
Autor: Ulrich Jarry, Megane Bostoen, Jérome Archambeau, Raphaël Pineau, Laura Chaillot, Florence Jouan, Hélène Solhi, Hugo Ferrari, Rémy Le Guevel, Valentine Mennessier, Hervé Lena, Romain Corre, Charles Ricordel, Thierry Guillaudeux, Rémy Pedeux
Publikováno v: PLoS ONE, Vol 19, Iss 6, p e0304914 (2024)
Lung cancer is one of the most common and deadliest cancers. Preclinical models are essential to study new therapies and combinations taking tumor genetics into account. We have established cell lines expressing the luciferase gene from lines with va
Externí odkaz: https://doaj.org/article/b617489982e245cfb967617c5f9cdb27
Zobrazit plný text záznamu
2
Akademický článek
Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
Autor: Emna Mahfoudhi, Charles Ricordel, Gwendoline Lecuyer, Cécile Mouric, Hervé Lena, Rémy Pedeux
Publikováno v: Frontiers in Oncology, Vol 12 (2022)
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are currently recommended as first-line treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR-activating mutations. Third-generation (3rd G) EGFR-TKIs, including
Externí odkaz: https://doaj.org/article/c4e8aa0f3f654af4bc84608754228119
Zobrazit plný text záznamu
3
Akademický článek
Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer
Autor: Nicolas Jaksic, Enrique Chajon, Julien Bellec, Romain Corre, Charles Ricordel, Bertrand de Latour, Hervé Lena, Ulrike Schick, Renaud de Crevoisier, Joël Castelli
Publikováno v: Radiation Oncology, Vol 13, Iss 1, Pp 1-8 (2018)
Abstract Background We aimed to evaluate the toxicity, loco-regional control (LRC) and overall survival (OS) associated with accelerated intensity-modulated radiotherapy (IMRT) for locally advanced lung cancer. Methods Seventy-three patients were con
Externí odkaz: https://doaj.org/article/54bfd339199a48e6b73558e922281bff
Zobrazit plný text záznamu
4
Akademický článek
Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB).
Autor: Christos Chouaid, Mathieu Salaün, Valérie Gounant, Michel Febvre, Jean-Michel Vergnon, Vincent Jouniaux, Clément Fournier, Samy Lachkar, Christophe Hermant, Christophe Raspaud, Xavier Quantin, Jean-Jacques Quiot, Anita Molard, Charles Dayen, Charles-Hugo Marquette, Hervé Lena, Gérard Zalcman, Luc Thiberville
Publikováno v: PLoS ONE, Vol 14, Iss 1, p e0208992 (2019)
This two-step study evaluated the cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for presurgery staging of non-small cell lung cancer (NSCLC) in France (EVIEPEB; ClinicalTrial.gov identifier NCT0096
Externí odkaz: https://doaj.org/article/6c30fecf15b548eca40de9f58054910d
Zobrazit plný text záznamu
5
Akademický článek
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
Autor: Jacques Cadranel, Alexis B. Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse
Publikováno v: ERJ Open Research, Vol 4, Iss 1 (2018)
Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK+) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study includ
Externí odkaz: https://doaj.org/article/202e9719c04a4ff99eb02f9055c1241b
Zobrazit plný text záznamu
8
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort
Autor: Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v: Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af408a468c8868241dcd48589bf78d34
https://doi.org/10.1016/j.lungcan.2021.10.017
Zobrazit plný text záznamu
10
Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer
Autor: Jérôme Doyen, Joël Castelli, Enrique Chajon, F. Thillays, Hervé Lena, Pierre-Yves Bondiau, Stéphane Supiot, R. de Crevoisier, Charles Ricordel, Loig Vaugier, Line Claude, J. Bellec, L. Duvergé
Publikováno v: Lung Cancer. 157:100-108
The duration of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) may affect patient outcomes. We aimed to determine the impact of a continuous versus discontinuous SBRT schedule on local control (LC) and overal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497c8515265e9f3cb42e1af829cbc28e
https://doi.org/10.1016/j.lungcan.2021.05.016
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje